1. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60: 505–514
2. Balz V, Prisack HB, Bier H, Bojar H (2002) Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families. Cancer Genet Cytogenet 138: 120–127
3. Borresen A, Andersen T, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjord J, Ottestad L, Smith-Sorensen B, Hovig E, Malkin D (1992) Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52: 3234–3236
4. Bukholm I, Nesland J, Karesen R, Jacobsen U, Borresen-Dale A (1997) Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas. Virchows Arch 431: 317–321
5. Buyru N, Tigli H, Dalay N (2003) P53 codon 72 polymorphism in breast cancer. Oncol Rep 10: 711–714